May 25, 2026
Eli Lilly (LLY) Stock Climbs on Breakthrough VERVE-102 Gene Therapy Results
Eli Lilly (LLY) stock climbs after VERVE-102 Heart-2 trial shows sustained LDL-C reduction up to 62% with strong safety data and Phase 2 plans confirmed.
The post Eli Lilly (LLY) Stock Climbs on Breakthrough VERVE-102 Gene Therapy Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 9 hours ago
Micron (MU) Earnings and PCE Data: Critical Tests for Tech Stocks This Week
- 9 hours ago
Micron (MU) Stock Price Prediction: What to Expect Through 2031
- 9 hours ago
Five Key Stocks and Inflation Data Set to Drive Markets Next Week
- 12 hours ago
SpaceX (SPCX) Stock: 5-Year Price Forecast and Valuation Analysis
- 12 hours ago
OpenAI vs Anthropic IPO Showdown: Which AI Giant Makes the Smarter Investment?